View ValuationBal Pharma 将来の成長Future 基準チェック /06現在、 Bal Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長18.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Aug 13First quarter 2027 earnings released: EPS: ₹0.71 (vs ₹0.13 in 1Q 2026)First quarter 2027 results: EPS: ₹0.71 (up from ₹0.13 in 1Q 2026). Revenue: ₹890.5m (up 35% from 1Q 2026). Net income: ₹11.2m (up 460% from 1Q 2026). Profit margin: 1.3% (up from 0.3% in 1Q 2026). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Aug 05Bal Pharma Limited to Report Q1, 2027 Results on Aug 12, 2026Bal Pharma Limited announced that they will report Q1, 2027 results on Aug 12, 2026New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹1.44b market cap, or US$15.0m).Reported Earnings • May 28Full year 2026 earnings released: EPS: ₹3.95 (vs ₹4.55 in FY 2025)Full year 2026 results: EPS: ₹3.95 (down from ₹4.55 in FY 2025). Revenue: ₹3.14b (up 3.5% from FY 2025). Net income: ₹62.8m (down 13% from FY 2025). Profit margin: 2.0% (down from 2.4% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • May 27+ 1 more updateBal Pharma Limited Recommends DividendBAL PHARMA LIMITED announced that its Board of Directors has recommended a dividend of INR 1.20 per equity share of INR 10 each i.e 12%, which is subject to the approval of members at the ensuing Annual General Meeting of the Company.Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹92.65, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.Buy Or Sell Opportunity • May 25Now 30% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to ₹88.57. The fair value is estimated to be ₹68.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 34%.お知らせ • May 18Bal Pharma Limited to Report Q4, 2026 Results on May 27, 2026Bal Pharma Limited announced that they will report Q4, 2026 results on May 27, 2026Buy Or Sell Opportunity • May 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to ₹81.22. The fair value is estimated to be ₹67.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 34%.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹69.76, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 2.6% over the past three years.Reported Earnings • Feb 13Third quarter 2026 earnings released: EPS: ₹1.12 (vs ₹1.87 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.12 (down from ₹1.87 in 3Q 2025). Revenue: ₹880.2m (up 14% from 3Q 2025). Net income: ₹17.8m (down 40% from 3Q 2025). Profit margin: 2.0% (down from 3.8% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Feb 03Bal Pharma Limited to Report Q3, 2026 Results on Feb 11, 2026Bal Pharma Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹0.45 (vs ₹0.65 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.45 (down from ₹0.65 in 2Q 2025). Revenue: ₹751.4m (up 2.0% from 2Q 2025). Net income: ₹7.10m (down 32% from 2Q 2025). Profit margin: 0.9% (down from 1.4% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Nov 04Bal Pharma Limited to Report Q2, 2026 Results on Nov 12, 2025Bal Pharma Limited announced that they will report Q2, 2026 results on Nov 12, 2025Buy Or Sell Opportunity • Oct 21Now 21% overvaluedOver the last 90 days, the stock has fallen 16% to ₹81.70. The fair value is estimated to be ₹67.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 37%.Upcoming Dividend • Sep 11Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 18 September 2025. Payment date: 25 October 2025. Payout ratio is a comfortable 26% but the company is paying out more than the cash it is generating. Trailing yield: 1.3%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).Declared Dividend • Aug 13Dividend of ₹1.20 announcedDividend of ₹1.20 is the same as last year. Ex-date: 18th September 2025 Payment date: 25th October 2025 Dividend yield will be 1.3%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but not covered by cash flows (124% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 39% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Aug 12Bal Pharma Limited, Annual General Meeting, Sep 25, 2025Bal Pharma Limited, Annual General Meeting, Sep 25, 2025, at 11:30 Indian Standard Time.Reported Earnings • Aug 12First quarter 2026 earnings released: EPS: ₹0.13 (vs ₹0.16 in 1Q 2025)First quarter 2026 results: EPS: ₹0.13 (down from ₹0.16 in 1Q 2025). Revenue: ₹665.9m (down 10% from 1Q 2025). Net income: ₹2.01m (down 23% from 1Q 2025). Profit margin: 0.3% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Jul 29Bal Pharma Limited to Report Q1, 2026 Results on Aug 11, 2025Bal Pharma Limited announced that they will report Q1, 2026 results on Aug 11, 2025Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Deputy GM of Internal Audit, Legal and Compliances & Non-Executive and Non-Independent Director Ravindra Kothari was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 30Full year 2025 earnings released: EPS: ₹4.56 (vs ₹4.68 in FY 2024)Full year 2025 results: EPS: ₹4.56 (down from ₹4.68 in FY 2024). Revenue: ₹3.05b (down 10.0% from FY 2024). Net income: ₹72.2m (down 2.4% from FY 2024). Profit margin: 2.4% (up from 2.2% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹1.44b market cap, or US$16.8m).Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹109, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years.Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹79.85, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 22% over the past three years.Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹0.65 (vs ₹0.62 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.65 (up from ₹0.62 in 2Q 2024). Revenue: ₹734.9m (down 21% from 2Q 2024). Net income: ₹10.4m (up 10% from 2Q 2024). Profit margin: 1.4% (up from 1.0% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 9% per year.お知らせ • Sep 26Bal Pharma Limited Approves DividendBal Pharma Limited approved dividend of INR 1.20 per equity share of INR 10 each i.e 12% at its AGM held on September 26, 2024.Upcoming Dividend • Sep 11Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 18 September 2024. Payment date: 25 October 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Indian dividend payers (1.0%). Higher than average of industry peers (0.6%).お知らせ • Aug 30+ 2 more updatesBal Pharma Limited to Report Q3, 2025 Results on Feb 14, 2025Bal Pharma Limited announced that they will report Q3, 2025 results on Feb 14, 2025Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹137, the stock trades at a trailing P/E ratio of 28.5x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 56% over the past three years.Declared Dividend • Aug 14Dividend increased to ₹1.20Dividend of ₹1.20 is 20% higher than last year. Ex-date: 18th September 2024 Payment date: 25th October 2024 Dividend yield will be 1.1%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 49% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Aug 13Bal Pharma Limited, Annual General Meeting, Sep 25, 2024Bal Pharma Limited, Annual General Meeting, Sep 25, 2024, at 11:30 Indian Standard Time.Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.06 in 1Q 2024)First quarter 2025 results: EPS: ₹0.16 (up from ₹0.06 in 1Q 2024). Revenue: ₹751.8m (up 6.8% from 1Q 2024). Net income: ₹2.59m (up 207% from 1Q 2024). Profit margin: 0.3% (up from 0.1% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.お知らせ • Jul 26Bal Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024Bal Pharma Limited announced that they will report Q1, 2025 results on Aug 12, 2024お知らせ • Jun 28Bal Pharma Limited Announces the Cessation of C. V. Srinivas as Independent Director, Chairman/Member of the Audit Committee, Nomination and Remuneration Committee, Stake Holders Relationship Committee & Corporate Social Responsibility CommitteesBal Pharma Limited announced that Dr. C. V. Srinivas, independent Director of the Company has completed his tenure of five years as independent Director and he ceases to be on the Board of the Company with effect from June 28, 2024. Consequently, Dr.C.V Srinivas shall also cease to be the Chairman/Member of the Audit Committee, Nomination and Remuneration Committee, Stake Holders Relationship Committee & Corporate Social Responsibility Committees of the Company.Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹121, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 27% over the past three years.お知らせ • May 29Bal Pharma Limited Recommends DividendBal Pharma Limited recommended dividend of INR 1.20/- per equity share of INR 10/- each i.e 12%, which is subject to the approval of members at the ensuing Annual General Meeting of the Company.New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (₹1.89b market cap, or US$22.6m).Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹4.94 (vs ₹1.64 in FY 2023)Full year 2024 results: EPS: ₹4.94 (up from ₹1.64 in FY 2023). Revenue: ₹3.42b (up 12% from FY 2023). Net income: ₹73.9m (up 187% from FY 2023). Profit margin: 2.2% (up from 0.8% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹89.65, the stock trades at a trailing P/E ratio of 40x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past three years.Reported Earnings • Feb 13Third quarter 2024 earnings released: EPS: ₹0.54 (vs ₹0.38 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.54 (up from ₹0.38 in 3Q 2023). Revenue: ₹817.6m (up 6.7% from 3Q 2023). Net income: ₹8.89m (up 55% from 3Q 2023). Profit margin: 1.1% (up from 0.8% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹130, the stock trades at a trailing P/E ratio of 63.6x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 150% over the past three years.New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.94b market cap, or US$23.3m).お知らせ • Jan 25Bal Pharma Limited to Report Q3, 2024 Results on Feb 12, 2024Bal Pharma Limited announced that they will report Q3, 2024 results on Feb 12, 2024Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹116, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 109% over the past three years.Board Change • Jan 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Additional Non-Independent Director Kotian Damodar was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹112, the stock trades at a trailing P/E ratio of 55x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years.Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹0.62 (vs ₹0.38 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.62 (up from ₹0.38 in 2Q 2023). Revenue: ₹926.8m (up 21% from 2Q 2023). Net income: ₹9.46m (up 65% from 2Q 2023). Profit margin: 1.0% (up from 0.8% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 21Bal Pharma Limited to Report Q2, 2024 Results on Nov 08, 2023Bal Pharma Limited announced that they will report Q2, 2024 results on Nov 08, 2023お知らせ • Sep 25Bal Pharma Limited Approves DividendBal Pharma Limited approved dividend of INR 1/- per Equity Share of INR 10/- each at its Annual General Meeting held on September 25, 2023.Upcoming Dividend • Sep 11Upcoming dividend of ₹1.00 per share at 1.0% yieldEligible shareholders must have bought the stock before 18 September 2023. Payment date: 25 October 2023. Payout ratio is a comfortable 61% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.3%). Higher than average of industry peers (0.9%).Reported Earnings • Aug 12First quarter 2024 earnings released: EPS: ₹0.06 (vs ₹0.19 in 1Q 2023)First quarter 2024 results: EPS: ₹0.06 (down from ₹0.19 in 1Q 2023). Revenue: ₹705.4m (up 1.0% from 1Q 2023). Net income: ₹843.0k (down 70% from 1Q 2023). Profit margin: 0.1% (down from 0.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 12Bal Pharma Limited, Annual General Meeting, Sep 25, 2023Bal Pharma Limited, Annual General Meeting, Sep 25, 2023, at 10:30 Indian Standard Time.お知らせ • Aug 03Bal Pharma Limited to Report Q1, 2024 Results on Aug 11, 2023Bal Pharma Limited announced that they will report Q1, 2024 results on Aug 11, 2023お知らせ • Jul 18Bal Pharma Limited Appoints Abdul Basith as Company Secretary and Compliance OfficerBal Pharma Limited announced that Board of Directors of the Company at their meeting held on July 11, 2023 has inter alia appointed Mr. Abdul Basith (M.No A70640), as Company Secretary and Compliance officer of the Company.Qualification: ACS. Experience: Over 6 years in Company Secretarial matters.お知らせ • Jun 02Bal Pharma Limited Appoints Nicola Neeladri as Additional DirectorBal Pharma Limited Board of Directors of the Company vide a resolution passed by circulation has appointed Ms. Nicola Neeladri as Additional Director of the Company to hold office from May 23, 2023 until the conclusion of upcoming General Meeting of the Company.お知らせ • May 31Bal Pharma Limited Recommends DividendBal Pharma Limited at its board meeting held on May 29, 2023 recommended dividend of INR 1.0 per equity share of INR 10.0 each, payable subject to the approval of members at the upcoming annual general meeting of the company.Reported Earnings • May 31Full year 2023 earnings released: EPS: ₹1.67 (vs ₹3.79 in FY 2022)Full year 2023 results: EPS: ₹1.67 (down from ₹3.79 in FY 2022). Revenue: ₹3.05b (up 8.5% from FY 2022). Net income: ₹25.7m (down 54% from FY 2022). Profit margin: 0.8% (down from 2.0% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.お知らせ • May 17Bal Pharma Limited to Report Q4, 2023 Results on May 29, 2023Bal Pharma Limited announced that they will report Q4, 2023 results on May 29, 2023Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹85.18, the stock trades at a trailing P/E ratio of 45.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹73.77, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 80% over the past three years.Reported Earnings • Feb 07Third quarter 2023 earnings releasedThird quarter 2023 results: EPS: ₹0.38. Revenue: ₹770.8m (up 11% from 3Q 2022). Net income: ₹5.75m (down 10% from 3Q 2022). Profit margin: 0.7% (down from 0.9% in 3Q 2022).お知らせ • Jan 28Bal Pharma Limited to Report Q3, 2023 Results on Feb 06, 2023Bal Pharma Limited announced that they will report Q3, 2023 results on Feb 06, 2023お知らせ • Nov 25Bal Pharma Limited Announces Resignation of Mr. G. Rengarajan as Chief Financial OfficerBal Pharma Limited announced the Resignation of Mr. G. Rengarajan as Chief Financial Officer (CFO) as CFO of the Company from the closure of business hours on November 24, 2022. The resignation is purely on account of health reason and other personal commitments and there are no other material reasons than the one mentioned herewith.Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.07 (vs ₹0.97 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.07 (down from ₹0.97 in 2Q 2022). Revenue: ₹756.0m (up 11% from 2Q 2022). Net income: ₹1.14m (down 92% from 2Q 2022). Profit margin: 0.2% (down from 2.0% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 05Bal Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022Bal Pharma Limited announced that they will report Q2, 2023 results on Nov 14, 2022Board Change • Oct 31High number of new directorsAdditional Non-Independent Director Kotian Damodar was the last director to join the board, commencing their role in 2022.お知らせ • Sep 20Bal Pharma Limited Declares DividendBal Pharma Limited at its annual general meeting held on September 19, 2022, to declare dividend of Re.1 per Equity Share of INR 10 each.Upcoming Dividend • Sep 06Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 13 September 2022. Payment date: 19 October 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.6%). In line with average of industry peers (1.0%).お知らせ • Aug 26Bal Pharma Limited, Annual General Meeting, Sep 19, 2022Bal Pharma Limited, Annual General Meeting, Sep 19, 2022, at 11:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2022; to declare dividend of INR 1 per Equity Share of INR 10/- each; to appoint Statutory Auditors from the conclusion of this 35th Annual General Meeting until the conclusion of the 40th Annual General Meeting and to fix their remuneration; to consider Adoption of new Set of Memorandum of Association as per the provisions of the Companies Act, 2013; and to consider any other matters.Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: ₹0.19 (vs ₹1.09 in 1Q 2022)First quarter 2023 results: EPS: ₹0.19 (down from ₹1.09 in 1Q 2022). Revenue: ₹700.8m (down 1.0% from 1Q 2022). Net income: ₹2.82m (down 83% from 1Q 2022). Profit margin: 0.4% (down from 2.3% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 30Bal Pharma Limited to Report Q1, 2023 Results on Aug 11, 2022Bal Pharma Limited announced that they will report Q1, 2023 results on Aug 11, 2022Reported Earnings • Jun 05Full year 2022 earnings released: EPS: ₹3.79 (vs ₹3.34 in FY 2021)Full year 2022 results: EPS: ₹3.79 (up from ₹3.34 in FY 2021). Revenue: ₹2.81b (up 12% from FY 2021). Net income: ₹56.1m (up 18% from FY 2021). Profit margin: 2.0% (up from 1.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.お知らせ • May 31+ 1 more updateBal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent)The board of directors of Bal Pharma Limited at its meeting held on May 30, 2022, appointed Mr. Kotian Chittananda Damodar (DIN # 09613054) as Additional Director (Non Independent) of the Company.Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. MD & Executive Director Shailesh Siroya is the most experienced director on the board, commencing their role in 1997. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.32 (up from ₹0.22 in 3Q 2021). Revenue: ₹699.2m (up 11% from 3Q 2021). Net income: ₹6.40m (up 102% from 3Q 2021). Profit margin: 0.9% (up from 0.5% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹127, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 66% over the past three years.Upcoming Dividend • Sep 09Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 16 September 2021. Payment date: 24 October 2021. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.8%).Reported Earnings • Aug 12First quarter 2022 earnings released: EPS ₹1.09 (vs ₹0.30 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹709.6m (up 36% from 1Q 2021). Net income: ₹16.2m (up 284% from 1Q 2021). Profit margin: 2.3% (up from 0.8% in 1Q 2021). The increase in margin was driven by higher revenue.Reported Earnings • Jul 03Full year 2021 earnings released: EPS ₹3.34 (vs ₹8.62 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹2.51b (up 46% from FY 2020). Net income: ₹47.4m (up ₹169.6m from FY 2020). Profit margin: 1.9% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • May 26Bal Pharma Ltd Announces the Launch of Favipiravir Formulation into Indian Market, Under the Brand Name BALfluBal Pharma Ltd. announced the launch of Favipiravir formulation into Indian market, under the brand name BALflu. Favipiravir is an emerging anti viral drug used for patients with mild to moderate Covid-19 infection. This formulation is available in tablets form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus. BALflu (Favipiravir) is a broad spectrum formulation also used in the treatment of 53 types of Influenza virus including seasonal strains such as Ebola virus, arenavirus, bunyavirus, flovirus, west nile virus, food & mouth disease virus and lassa virus. BALflu (Favipiravir) is approved by Drug Controller General of India (DCGI) for emergency use for the treatment of COVID-19 with an recommended dosage of 1800 mg on the first day followed by 800 mg from day 2 to 14. BALflu (Favipiravir) is made available across all the major markets in India as a prescription drug.お知らせ • Mar 19Bal Pharma Limited announced that it expects to receive INR 32.5 million in fundingBal Pharma Limited (BSE:524824) announced a private placement of 6,50,000 common shares at a par value of INR 10 per share at a premium of INR 40 ,at a issue price of INR 50 per shares for gross proceeds of INR 32,500,000 on March 17, 2021.The shares will be issued on preferential basis. The transaction will include participation from Shailesh Siroya. The transaction was approved by the board of directors.Is New 90 Day High Low • Mar 15New 90-day high: ₹60.50The company is up 5.0% from a price of ₹57.80 on 15 December 2020. Underperformed the Indian market, which is up 14% over the last 90 days. Exceeded the Pharmaceuticals industry, which is down 1.0% over the same period.Reported Earnings • Feb 23Third quarter 2021 earnings released: EPS ₹0.22 (vs ₹2.62 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹632.2m (up 46% from 3Q 2020). Net income: ₹4.01m (up ₹41.1m from 3Q 2020). Profit margin: 0.6% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 86% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Jan 21Bal Pharma Limited to Report Q3, 2021 Results on Feb 11, 2021Bal Pharma Limited announced that they will report Q3, 2021 results on Feb 11, 2021お知らせ • Dec 29Bal Pharma Limited Appoints Jatish Sheth as Additional DirectorThe Board of Directors of the Bal Pharma Limited appointed Mr.Jatish Sheth as Additional Director on the Board of the Company with effect from December 28, 2020 and to hold office till the conclusion of the next Annual General Meeting of the Company. The management will seek the approval of members for regularizing his appointment for a further period of 5 years. Mr.Jatish Sheth is the Director of Srushti Pharmaceuticals Pvt Ltd. with over 26 years of experience in pharmaceutical industry . Mr.Jatish Sheth is not related to any Directors or KMP's of the Company and is not disqualified from holding the office of Director of the company.Reported Earnings • Nov 15Second quarter 2021 earnings released: EPS ₹0.30The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹646.2m (up 44% from 2Q 2020). Net income: ₹4.24m (up ₹24.1m from 2Q 2020). Profit margin: 0.7% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 104% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.お知らせ • Nov 03Bal Pharma Limited to Report Q2, 2021 Results on Nov 11, 2020Bal Pharma Limited announced that they will report Q2, 2021 results on Nov 11, 2020Is New 90 Day High Low • Oct 08New 90-day high: ₹54.80The company is up 29% from its price of ₹42.45 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period.お知らせ • Sep 09Bal Pharma Limited announced that it expects to receive INR 70 million in fundingBal Pharma Limited (BSE:524824) announced a private placement of 1,400,000 warrants at a price of INR 50 for a total gross proceeds of INR 700,000,000 on September 8, 2020. The warrants will be issued on preferential basis. The transaction will include participation from promoters. The transaction is subject to approval of shareholders at the annual general meeting of the company. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bal Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:524824 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20263,34172N/AN/AN/A3/31/20263,11763119304N/A12/31/20253,09581N/AN/AN/A9/30/20252,9496849192N/A6/30/20252,94672N/AN/AN/A3/31/20253,0317215203N/A12/31/20243,15873N/AN/AN/A9/30/20243,24377133304N/A6/30/20243,43276N/AN/AN/A3/31/20243,39274118228N/A12/31/20233,27035N/AN/AN/A9/30/20233,22032N/AN/AN/A6/30/20233,04824N/AN/AN/A3/31/20233,04226-162-15N/A12/31/20222,95829N/AN/AN/A9/30/20222,88430N/AN/AN/A6/30/20222,80243N/AN/AN/A3/31/20222,81256183268N/A12/31/20212,78072N/AN/AN/A9/30/20212,71869247257N/A6/30/20212,69259N/AN/AN/A3/31/20212,50547190223N/A12/31/20202,135-34N/AN/AN/A9/30/20201,936-73N/AN/AN/A6/30/20201,741-95N/AN/AN/A3/31/20201,711-122N/A232N/A12/31/20191,924-52N/AN/AN/A9/30/20192,081-15N/AN/AN/A6/30/20192,206-21N/AN/AN/A3/31/20192,25038N/A78N/A12/31/20182,26429N/AN/AN/A3/31/20182,09328N/A6N/A12/31/20172,11114N/AN/AN/A3/31/20172,28918N/A63N/A12/31/20162,210-3N/AN/AN/A9/30/20162,12013N/AN/AN/A6/30/20162,01616N/AN/AN/A3/31/20161,98314N/A-194N/A12/31/20151,95947N/AN/AN/A9/30/20151,92533N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 524824の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 524824の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 524824の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 524824の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 524824の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 524824の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/20 14:00終値2026/08/20 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bal Pharma Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Aug 13First quarter 2027 earnings released: EPS: ₹0.71 (vs ₹0.13 in 1Q 2026)First quarter 2027 results: EPS: ₹0.71 (up from ₹0.13 in 1Q 2026). Revenue: ₹890.5m (up 35% from 1Q 2026). Net income: ₹11.2m (up 460% from 1Q 2026). Profit margin: 1.3% (up from 0.3% in 1Q 2026). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Aug 05Bal Pharma Limited to Report Q1, 2027 Results on Aug 12, 2026Bal Pharma Limited announced that they will report Q1, 2027 results on Aug 12, 2026
New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹1.44b market cap, or US$15.0m).
Reported Earnings • May 28Full year 2026 earnings released: EPS: ₹3.95 (vs ₹4.55 in FY 2025)Full year 2026 results: EPS: ₹3.95 (down from ₹4.55 in FY 2025). Revenue: ₹3.14b (up 3.5% from FY 2025). Net income: ₹62.8m (down 13% from FY 2025). Profit margin: 2.0% (down from 2.4% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • May 27+ 1 more updateBal Pharma Limited Recommends DividendBAL PHARMA LIMITED announced that its Board of Directors has recommended a dividend of INR 1.20 per equity share of INR 10 each i.e 12%, which is subject to the approval of members at the ensuing Annual General Meeting of the Company.
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹92.65, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.
Buy Or Sell Opportunity • May 25Now 30% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to ₹88.57. The fair value is estimated to be ₹68.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 34%.
お知らせ • May 18Bal Pharma Limited to Report Q4, 2026 Results on May 27, 2026Bal Pharma Limited announced that they will report Q4, 2026 results on May 27, 2026
Buy Or Sell Opportunity • May 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to ₹81.22. The fair value is estimated to be ₹67.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 34%.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹69.76, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 2.6% over the past three years.
Reported Earnings • Feb 13Third quarter 2026 earnings released: EPS: ₹1.12 (vs ₹1.87 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.12 (down from ₹1.87 in 3Q 2025). Revenue: ₹880.2m (up 14% from 3Q 2025). Net income: ₹17.8m (down 40% from 3Q 2025). Profit margin: 2.0% (down from 3.8% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Feb 03Bal Pharma Limited to Report Q3, 2026 Results on Feb 11, 2026Bal Pharma Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026
Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹0.45 (vs ₹0.65 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.45 (down from ₹0.65 in 2Q 2025). Revenue: ₹751.4m (up 2.0% from 2Q 2025). Net income: ₹7.10m (down 32% from 2Q 2025). Profit margin: 0.9% (down from 1.4% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Nov 04Bal Pharma Limited to Report Q2, 2026 Results on Nov 12, 2025Bal Pharma Limited announced that they will report Q2, 2026 results on Nov 12, 2025
Buy Or Sell Opportunity • Oct 21Now 21% overvaluedOver the last 90 days, the stock has fallen 16% to ₹81.70. The fair value is estimated to be ₹67.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 37%.
Upcoming Dividend • Sep 11Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 18 September 2025. Payment date: 25 October 2025. Payout ratio is a comfortable 26% but the company is paying out more than the cash it is generating. Trailing yield: 1.3%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).
Declared Dividend • Aug 13Dividend of ₹1.20 announcedDividend of ₹1.20 is the same as last year. Ex-date: 18th September 2025 Payment date: 25th October 2025 Dividend yield will be 1.3%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but not covered by cash flows (124% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 39% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Aug 12Bal Pharma Limited, Annual General Meeting, Sep 25, 2025Bal Pharma Limited, Annual General Meeting, Sep 25, 2025, at 11:30 Indian Standard Time.
Reported Earnings • Aug 12First quarter 2026 earnings released: EPS: ₹0.13 (vs ₹0.16 in 1Q 2025)First quarter 2026 results: EPS: ₹0.13 (down from ₹0.16 in 1Q 2025). Revenue: ₹665.9m (down 10% from 1Q 2025). Net income: ₹2.01m (down 23% from 1Q 2025). Profit margin: 0.3% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Jul 29Bal Pharma Limited to Report Q1, 2026 Results on Aug 11, 2025Bal Pharma Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Deputy GM of Internal Audit, Legal and Compliances & Non-Executive and Non-Independent Director Ravindra Kothari was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 30Full year 2025 earnings released: EPS: ₹4.56 (vs ₹4.68 in FY 2024)Full year 2025 results: EPS: ₹4.56 (down from ₹4.68 in FY 2024). Revenue: ₹3.05b (down 10.0% from FY 2024). Net income: ₹72.2m (down 2.4% from FY 2024). Profit margin: 2.4% (up from 2.2% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹1.44b market cap, or US$16.8m).
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹109, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years.
Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹79.85, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 22% over the past three years.
Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹0.65 (vs ₹0.62 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.65 (up from ₹0.62 in 2Q 2024). Revenue: ₹734.9m (down 21% from 2Q 2024). Net income: ₹10.4m (up 10% from 2Q 2024). Profit margin: 1.4% (up from 1.0% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 9% per year.
お知らせ • Sep 26Bal Pharma Limited Approves DividendBal Pharma Limited approved dividend of INR 1.20 per equity share of INR 10 each i.e 12% at its AGM held on September 26, 2024.
Upcoming Dividend • Sep 11Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 18 September 2024. Payment date: 25 October 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Indian dividend payers (1.0%). Higher than average of industry peers (0.6%).
お知らせ • Aug 30+ 2 more updatesBal Pharma Limited to Report Q3, 2025 Results on Feb 14, 2025Bal Pharma Limited announced that they will report Q3, 2025 results on Feb 14, 2025
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹137, the stock trades at a trailing P/E ratio of 28.5x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 56% over the past three years.
Declared Dividend • Aug 14Dividend increased to ₹1.20Dividend of ₹1.20 is 20% higher than last year. Ex-date: 18th September 2024 Payment date: 25th October 2024 Dividend yield will be 1.1%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 49% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Aug 13Bal Pharma Limited, Annual General Meeting, Sep 25, 2024Bal Pharma Limited, Annual General Meeting, Sep 25, 2024, at 11:30 Indian Standard Time.
Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.06 in 1Q 2024)First quarter 2025 results: EPS: ₹0.16 (up from ₹0.06 in 1Q 2024). Revenue: ₹751.8m (up 6.8% from 1Q 2024). Net income: ₹2.59m (up 207% from 1Q 2024). Profit margin: 0.3% (up from 0.1% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
お知らせ • Jul 26Bal Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024Bal Pharma Limited announced that they will report Q1, 2025 results on Aug 12, 2024
お知らせ • Jun 28Bal Pharma Limited Announces the Cessation of C. V. Srinivas as Independent Director, Chairman/Member of the Audit Committee, Nomination and Remuneration Committee, Stake Holders Relationship Committee & Corporate Social Responsibility CommitteesBal Pharma Limited announced that Dr. C. V. Srinivas, independent Director of the Company has completed his tenure of five years as independent Director and he ceases to be on the Board of the Company with effect from June 28, 2024. Consequently, Dr.C.V Srinivas shall also cease to be the Chairman/Member of the Audit Committee, Nomination and Remuneration Committee, Stake Holders Relationship Committee & Corporate Social Responsibility Committees of the Company.
Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹121, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 27% over the past three years.
お知らせ • May 29Bal Pharma Limited Recommends DividendBal Pharma Limited recommended dividend of INR 1.20/- per equity share of INR 10/- each i.e 12%, which is subject to the approval of members at the ensuing Annual General Meeting of the Company.
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (₹1.89b market cap, or US$22.6m).
Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹4.94 (vs ₹1.64 in FY 2023)Full year 2024 results: EPS: ₹4.94 (up from ₹1.64 in FY 2023). Revenue: ₹3.42b (up 12% from FY 2023). Net income: ₹73.9m (up 187% from FY 2023). Profit margin: 2.2% (up from 0.8% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹89.65, the stock trades at a trailing P/E ratio of 40x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past three years.
Reported Earnings • Feb 13Third quarter 2024 earnings released: EPS: ₹0.54 (vs ₹0.38 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.54 (up from ₹0.38 in 3Q 2023). Revenue: ₹817.6m (up 6.7% from 3Q 2023). Net income: ₹8.89m (up 55% from 3Q 2023). Profit margin: 1.1% (up from 0.8% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹130, the stock trades at a trailing P/E ratio of 63.6x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 150% over the past three years.
New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.94b market cap, or US$23.3m).
お知らせ • Jan 25Bal Pharma Limited to Report Q3, 2024 Results on Feb 12, 2024Bal Pharma Limited announced that they will report Q3, 2024 results on Feb 12, 2024
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹116, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 109% over the past three years.
Board Change • Jan 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Additional Non-Independent Director Kotian Damodar was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹112, the stock trades at a trailing P/E ratio of 55x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years.
Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹0.62 (vs ₹0.38 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.62 (up from ₹0.38 in 2Q 2023). Revenue: ₹926.8m (up 21% from 2Q 2023). Net income: ₹9.46m (up 65% from 2Q 2023). Profit margin: 1.0% (up from 0.8% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 21Bal Pharma Limited to Report Q2, 2024 Results on Nov 08, 2023Bal Pharma Limited announced that they will report Q2, 2024 results on Nov 08, 2023
お知らせ • Sep 25Bal Pharma Limited Approves DividendBal Pharma Limited approved dividend of INR 1/- per Equity Share of INR 10/- each at its Annual General Meeting held on September 25, 2023.
Upcoming Dividend • Sep 11Upcoming dividend of ₹1.00 per share at 1.0% yieldEligible shareholders must have bought the stock before 18 September 2023. Payment date: 25 October 2023. Payout ratio is a comfortable 61% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.3%). Higher than average of industry peers (0.9%).
Reported Earnings • Aug 12First quarter 2024 earnings released: EPS: ₹0.06 (vs ₹0.19 in 1Q 2023)First quarter 2024 results: EPS: ₹0.06 (down from ₹0.19 in 1Q 2023). Revenue: ₹705.4m (up 1.0% from 1Q 2023). Net income: ₹843.0k (down 70% from 1Q 2023). Profit margin: 0.1% (down from 0.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 12Bal Pharma Limited, Annual General Meeting, Sep 25, 2023Bal Pharma Limited, Annual General Meeting, Sep 25, 2023, at 10:30 Indian Standard Time.
お知らせ • Aug 03Bal Pharma Limited to Report Q1, 2024 Results on Aug 11, 2023Bal Pharma Limited announced that they will report Q1, 2024 results on Aug 11, 2023
お知らせ • Jul 18Bal Pharma Limited Appoints Abdul Basith as Company Secretary and Compliance OfficerBal Pharma Limited announced that Board of Directors of the Company at their meeting held on July 11, 2023 has inter alia appointed Mr. Abdul Basith (M.No A70640), as Company Secretary and Compliance officer of the Company.Qualification: ACS. Experience: Over 6 years in Company Secretarial matters.
お知らせ • Jun 02Bal Pharma Limited Appoints Nicola Neeladri as Additional DirectorBal Pharma Limited Board of Directors of the Company vide a resolution passed by circulation has appointed Ms. Nicola Neeladri as Additional Director of the Company to hold office from May 23, 2023 until the conclusion of upcoming General Meeting of the Company.
お知らせ • May 31Bal Pharma Limited Recommends DividendBal Pharma Limited at its board meeting held on May 29, 2023 recommended dividend of INR 1.0 per equity share of INR 10.0 each, payable subject to the approval of members at the upcoming annual general meeting of the company.
Reported Earnings • May 31Full year 2023 earnings released: EPS: ₹1.67 (vs ₹3.79 in FY 2022)Full year 2023 results: EPS: ₹1.67 (down from ₹3.79 in FY 2022). Revenue: ₹3.05b (up 8.5% from FY 2022). Net income: ₹25.7m (down 54% from FY 2022). Profit margin: 0.8% (down from 2.0% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
お知らせ • May 17Bal Pharma Limited to Report Q4, 2023 Results on May 29, 2023Bal Pharma Limited announced that they will report Q4, 2023 results on May 29, 2023
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹85.18, the stock trades at a trailing P/E ratio of 45.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹73.77, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 80% over the past three years.
Reported Earnings • Feb 07Third quarter 2023 earnings releasedThird quarter 2023 results: EPS: ₹0.38. Revenue: ₹770.8m (up 11% from 3Q 2022). Net income: ₹5.75m (down 10% from 3Q 2022). Profit margin: 0.7% (down from 0.9% in 3Q 2022).
お知らせ • Jan 28Bal Pharma Limited to Report Q3, 2023 Results on Feb 06, 2023Bal Pharma Limited announced that they will report Q3, 2023 results on Feb 06, 2023
お知らせ • Nov 25Bal Pharma Limited Announces Resignation of Mr. G. Rengarajan as Chief Financial OfficerBal Pharma Limited announced the Resignation of Mr. G. Rengarajan as Chief Financial Officer (CFO) as CFO of the Company from the closure of business hours on November 24, 2022. The resignation is purely on account of health reason and other personal commitments and there are no other material reasons than the one mentioned herewith.
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.07 (vs ₹0.97 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.07 (down from ₹0.97 in 2Q 2022). Revenue: ₹756.0m (up 11% from 2Q 2022). Net income: ₹1.14m (down 92% from 2Q 2022). Profit margin: 0.2% (down from 2.0% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 05Bal Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022Bal Pharma Limited announced that they will report Q2, 2023 results on Nov 14, 2022
Board Change • Oct 31High number of new directorsAdditional Non-Independent Director Kotian Damodar was the last director to join the board, commencing their role in 2022.
お知らせ • Sep 20Bal Pharma Limited Declares DividendBal Pharma Limited at its annual general meeting held on September 19, 2022, to declare dividend of Re.1 per Equity Share of INR 10 each.
Upcoming Dividend • Sep 06Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 13 September 2022. Payment date: 19 October 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.6%). In line with average of industry peers (1.0%).
お知らせ • Aug 26Bal Pharma Limited, Annual General Meeting, Sep 19, 2022Bal Pharma Limited, Annual General Meeting, Sep 19, 2022, at 11:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2022; to declare dividend of INR 1 per Equity Share of INR 10/- each; to appoint Statutory Auditors from the conclusion of this 35th Annual General Meeting until the conclusion of the 40th Annual General Meeting and to fix their remuneration; to consider Adoption of new Set of Memorandum of Association as per the provisions of the Companies Act, 2013; and to consider any other matters.
Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: ₹0.19 (vs ₹1.09 in 1Q 2022)First quarter 2023 results: EPS: ₹0.19 (down from ₹1.09 in 1Q 2022). Revenue: ₹700.8m (down 1.0% from 1Q 2022). Net income: ₹2.82m (down 83% from 1Q 2022). Profit margin: 0.4% (down from 2.3% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 30Bal Pharma Limited to Report Q1, 2023 Results on Aug 11, 2022Bal Pharma Limited announced that they will report Q1, 2023 results on Aug 11, 2022
Reported Earnings • Jun 05Full year 2022 earnings released: EPS: ₹3.79 (vs ₹3.34 in FY 2021)Full year 2022 results: EPS: ₹3.79 (up from ₹3.34 in FY 2021). Revenue: ₹2.81b (up 12% from FY 2021). Net income: ₹56.1m (up 18% from FY 2021). Profit margin: 2.0% (up from 1.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
お知らせ • May 31+ 1 more updateBal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent)The board of directors of Bal Pharma Limited at its meeting held on May 30, 2022, appointed Mr. Kotian Chittananda Damodar (DIN # 09613054) as Additional Director (Non Independent) of the Company.
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. MD & Executive Director Shailesh Siroya is the most experienced director on the board, commencing their role in 1997. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.32 (up from ₹0.22 in 3Q 2021). Revenue: ₹699.2m (up 11% from 3Q 2021). Net income: ₹6.40m (up 102% from 3Q 2021). Profit margin: 0.9% (up from 0.5% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹127, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 66% over the past three years.
Upcoming Dividend • Sep 09Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 16 September 2021. Payment date: 24 October 2021. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.8%).
Reported Earnings • Aug 12First quarter 2022 earnings released: EPS ₹1.09 (vs ₹0.30 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹709.6m (up 36% from 1Q 2021). Net income: ₹16.2m (up 284% from 1Q 2021). Profit margin: 2.3% (up from 0.8% in 1Q 2021). The increase in margin was driven by higher revenue.
Reported Earnings • Jul 03Full year 2021 earnings released: EPS ₹3.34 (vs ₹8.62 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹2.51b (up 46% from FY 2020). Net income: ₹47.4m (up ₹169.6m from FY 2020). Profit margin: 1.9% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • May 26Bal Pharma Ltd Announces the Launch of Favipiravir Formulation into Indian Market, Under the Brand Name BALfluBal Pharma Ltd. announced the launch of Favipiravir formulation into Indian market, under the brand name BALflu. Favipiravir is an emerging anti viral drug used for patients with mild to moderate Covid-19 infection. This formulation is available in tablets form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus. BALflu (Favipiravir) is a broad spectrum formulation also used in the treatment of 53 types of Influenza virus including seasonal strains such as Ebola virus, arenavirus, bunyavirus, flovirus, west nile virus, food & mouth disease virus and lassa virus. BALflu (Favipiravir) is approved by Drug Controller General of India (DCGI) for emergency use for the treatment of COVID-19 with an recommended dosage of 1800 mg on the first day followed by 800 mg from day 2 to 14. BALflu (Favipiravir) is made available across all the major markets in India as a prescription drug.
お知らせ • Mar 19Bal Pharma Limited announced that it expects to receive INR 32.5 million in fundingBal Pharma Limited (BSE:524824) announced a private placement of 6,50,000 common shares at a par value of INR 10 per share at a premium of INR 40 ,at a issue price of INR 50 per shares for gross proceeds of INR 32,500,000 on March 17, 2021.The shares will be issued on preferential basis. The transaction will include participation from Shailesh Siroya. The transaction was approved by the board of directors.
Is New 90 Day High Low • Mar 15New 90-day high: ₹60.50The company is up 5.0% from a price of ₹57.80 on 15 December 2020. Underperformed the Indian market, which is up 14% over the last 90 days. Exceeded the Pharmaceuticals industry, which is down 1.0% over the same period.
Reported Earnings • Feb 23Third quarter 2021 earnings released: EPS ₹0.22 (vs ₹2.62 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹632.2m (up 46% from 3Q 2020). Net income: ₹4.01m (up ₹41.1m from 3Q 2020). Profit margin: 0.6% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 86% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 21Bal Pharma Limited to Report Q3, 2021 Results on Feb 11, 2021Bal Pharma Limited announced that they will report Q3, 2021 results on Feb 11, 2021
お知らせ • Dec 29Bal Pharma Limited Appoints Jatish Sheth as Additional DirectorThe Board of Directors of the Bal Pharma Limited appointed Mr.Jatish Sheth as Additional Director on the Board of the Company with effect from December 28, 2020 and to hold office till the conclusion of the next Annual General Meeting of the Company. The management will seek the approval of members for regularizing his appointment for a further period of 5 years. Mr.Jatish Sheth is the Director of Srushti Pharmaceuticals Pvt Ltd. with over 26 years of experience in pharmaceutical industry . Mr.Jatish Sheth is not related to any Directors or KMP's of the Company and is not disqualified from holding the office of Director of the company.
Reported Earnings • Nov 15Second quarter 2021 earnings released: EPS ₹0.30The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹646.2m (up 44% from 2Q 2020). Net income: ₹4.24m (up ₹24.1m from 2Q 2020). Profit margin: 0.7% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 104% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 03Bal Pharma Limited to Report Q2, 2021 Results on Nov 11, 2020Bal Pharma Limited announced that they will report Q2, 2021 results on Nov 11, 2020
Is New 90 Day High Low • Oct 08New 90-day high: ₹54.80The company is up 29% from its price of ₹42.45 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period.
お知らせ • Sep 09Bal Pharma Limited announced that it expects to receive INR 70 million in fundingBal Pharma Limited (BSE:524824) announced a private placement of 1,400,000 warrants at a price of INR 50 for a total gross proceeds of INR 700,000,000 on September 8, 2020. The warrants will be issued on preferential basis. The transaction will include participation from promoters. The transaction is subject to approval of shareholders at the annual general meeting of the company.